TII
11.4.2022 13:18:04 CEST | Business Wire | Press release
Technology Innovation Institute (TII), a global research center and applied research pillar of Abu Dhabi’s Advanced Technology Research Council, today announced the launch of NOOR, the world’s largest Arabic natural language processing (NLP) model to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005085/en/
TII’s team of advanced researchers and Artificial Intelligence (AI) specialists, has joined forces with LightOn, a technology company that unlocks extreme-scale machine intelligence for businesses, to transform the Arabic NLP model. The NOOR model has the capability to carry out tasks beyond the domain of language - offering end-to-end pipeline high quality data, including crawling, filtering, and curation at scale. The model facilitates extreme-scale distributed training and serving – to deliver applications with efficient inference and model specialization.
Dr. Ray O. Johnson, CEO, TII and ASPIRE, said: “With this development, we are well on track to enhance our research capabilities and credentials as well as elevate the status of Abu Dhabi and the UAE as a serious research ecosystem. Our expert teams have demonstrated yet again that this region can achieve breakthrough R&D outcomes to impact the world.”
Dr. Ebtesam Almazrouei, Director, AI Cross-Center Unit, TII, said: “Large language models have taken the world of natural language processing by storm, and we are proud to introduce this cutting-edge model with 10 billion parameters - the world’s largest Arabic NLP model. The uniquely large Arabic dataset collected to train the model is the result of months of work that included curating, scrapping, and filtering of varied sources. A special thank you to the entire team that worked on this project to make NOOR the go-to exploration model in Arabic for academicians and businesses everywhere.”
Speaking on the launch, Prof. Mérouane Debbah, Chief Researcher, Digital Science Research Center and AI Cross-Center Unit, TII, said: “With NOOR, TII has expanded the scope of the modern standard Arabic model by leveraging know-how in large language models to build cross-disciplinary, cutting-edge expertise in this new generation of AI research.”
To curate the world’s largest high-quality cross-domain Arabic datasets, NOOR’s unique dataset of more than 30 billion words combines web data with books, poetry, news articles, and technical information to significantly widen the applicability of the model.
Dr. Ebtesam Almazrouei said the NOOR model is based on the popular Transformer architecture. As a decoder-only model, similar in structure to GPT-3, it is programmed to tackle generative tasks with architecture upgraded to reflect the latest developments in the world of machine learning, including improvements such as better positional embeddings. To help ensure quality at scale in the NOOR dataset, the TII team designed an automated filtering pipeline based on machine learning techniques. These tools identify text like quality references and safeguard the model from exposure to spam content.
Leveraging state-of-the-art 3D parallelism, NOOR was trained on a High-Performance Computing resource with 128 A100 GPUs, allowing for the distribution of computations and ensuring efficient use of the available hardware resources.
The Director of the AI Cross-Center Unit noted that this was only the first step in the Unit’s efforts to contribute to the wider UAE Strategy for Artificial Intelligence.
Named for the Arabic word "light", the model has been so called to establish the correlation of the Arabic language model to enlightening the mind.
About Technology Innovation Institute (TII)
For more information, visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005085/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
